Cargando…

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China

BACKGROUND: Inetetamab (cipterbin) is an innovative anti-HER2 humanized monoclonal antibody. The efficacy and safety of a combination of inetetamab and vinorelbine in the first-line treatment of human epidermal receptor positive (HER2+) metastatic breast cancer (MBC) have been confirmed. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoyu, Zhang, Peng, Li, Chao, Song, Xiang, Liu, Zhaoyun, Shao, Wenna, Li, Sumei, Wang, Xinzhao, Yu, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316697/ https://www.ncbi.nlm.nih.gov/pubmed/37404769 http://dx.doi.org/10.3389/fonc.2023.1136380

Ejemplares similares

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Li, Chao, et al.
Publicado: (2021)

Survival analysis and prognosis of patients with breast cancer with pleural metastasis
por: Li, Sumei, et al.
Publicado: (2023)

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
por: Deng, Lan, et al.
Publicado: (2023)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
por: Wang, Xinzhao, et al.
Publicado: (2021)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway
por: Shao, Wenna, et al.
Publicado: (2023)

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
por: Cui, Jinfang, et al.
Publicado: (2023)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
por: Liu, Binliang, et al.
Publicado: (2023)

Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
por: Yin, Sha, et al.
Publicado: (2022)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2021)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
por: Lakomy, Radek, et al.
Publicado: (2020)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
por: Novick, Diego, et al.
Publicado: (2022)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study
por: Yu, Ze, et al.
Publicado: (2022)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
por: Zhang, Lili, et al.
Publicado: (2021)

Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
por: Yuan, Chenxi, et al.
Publicado: (2019)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
por: Zhao, Lin, et al.
Publicado: (2019)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
por: Saijo, Ken, et al.
Publicado: (2023)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies
por: Yanada, Masamitsu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_keetojkaa0afstoqukn73ts0hc